Pharmacovigilance on MMR vaccine containing L-Zagreb mumps strain

Vaccine

Volumn 22, Issue 31-32, 2004, Pages 4135-4136

  Phadke, M A ^a   Patki, P S ^b   Kulkarni, P S ^b   Jadhav, S S ^b   Kapre, S V ^b  

^a Medical Education and Research   (India)

^b Serum Institute of India Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; MEASLES MUMPS RUBELLA VACCINE; MEASLES MUMPS VACCINE;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTHRALGIA; ASEPTIC MENINGITIS; AUTISM; COHORT ANALYSIS; CONVULSION; DRUG INDUCED DISEASE; DRUG SURVEILLANCE PROGRAM; DYSPNEA; ENCEPHALITIS; ENTERITIS; FEBRILE CONVULSION; FEVER; HEARING IMPAIRMENT; HUMAN; IMMUNIZATION; INDIA; LETTER; LYMPHADENOPATHY; MEASLES VACCINATION; MUMPS; MUMPS VIRUS; MYOSITIS; NONHUMAN; ORCHITIS; PAROTITIS; PATHOLOGICAL CRYING; PRIORITY JOURNAL; QUESTIONNAIRE; RASH; RESPIRATORY TRACT DISEASE; SIDE EFFECT; THROMBOCYTOPENIA; VACCINATION; VIRUS INFECTION; VIRUS STRAIN; VOMITING;

ADOLESCENT; ANAPHYLAXIS; DATA COLLECTION; FEMALE; HUMANS; INFANT; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS VIRUS; PRODUCT SURVEILLANCE, POSTMARKETING; VACCINATION;

EID: 4944245359     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.04.002     Document Type: Letter

References (8)

1. Jefferson T., Price D., Demicheli V. Bianco E European Research Program for Improved Vaccine Safety Surveillance (EUSAFEVAC) Project. Unintended events following immunization with MMR: a systematic review. Vaccine. 21(25-26):2003;3954-3960
2. Beck M., Welsz-Malecek R., Mesko-Prejac M., et al. Mumps vaccine L-Zagreb, prepared in chick fibroblasts. Part I. Production and field trials. J. Biol. Stand. 17(1):1989;85-90
3. Gogtay N.J., Mangalvedhekar S.S., Kshirsagar N.A. Adverse drug reaction monitoring in India and the postal survey as a useful tool for ADR detection. Pharmacoepidemiol Drug Safety. 9:2000;235-236
4. Ramkissoon A., Coovadia H.M., Loening W.E., Ndlovana M. Does whole-cell pertussis vaccine protect black South African infants? Assessment of post-vaccination events and antibody responses to pertussis toxin, filamentous haemagglutinin and agglutinogens 2 and 3. S. Afr. Med. J. 79(11):1991;645-649
5. Black S., Shinefield H., Ray P., Lewis E., Chen R., Glasser J., et al. Risk of hospitalization because of aseptic meningitis after measles-mumps- rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatr. Infect. Dis. J. 16(5):1997;500-503
6. da Cunha S.S., Rodrigues L.C., Barreto M.L., Dourado I. Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine. 20(7-8):2002;1106-1112
7. da Silveira C.M., Kmetzsch C.I., Mohrdieck R., Sperb A.F., Prevots D.R. The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. Int. J. Epidemiol. 31(5):2002;978-982
8. Pan American Health Organization PAHO. Special Program for Vaccines and Immunization. Evaluation of the Bahamas' MMR campaign, EPI Newslett 1999;21(1):4-5.